Interpace Biosciences, Inc. Stock Other OTC
Equities
IDXG
US46062X3035
Managed Healthcare
Financials (USD)
Sales 2022 | 31.84M | Sales 2023 | 40.21M | Capitalization | 4.69M |
---|---|---|---|---|---|
Net income 2022 | -22M | Net income 2023 | - | EV / Sales 2022 | 0.49 x |
Net Debt 2022 | 11.26M | Net Debt 2023 | 7.69M | EV / Sales 2023 | 0.31 x |
P/E ratio 2022 |
-0.2
x | P/E ratio 2023 |
6.03
x | Employees | - |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 72.42% |
Managers | Title | Age | Since |
---|---|---|---|
Thomas Burnell
CEO | Chief Executive Officer | 62 | 20-11-30 |
Director of Finance/CFO | 32 | 19-05-31 | |
Nicole Massoll
CTO | Chief Tech/Sci/R&D Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Vijay Aggarwal
BRD | Director/Board Member | 75 | 22-01-31 |
Joseph Keegan
BRD | Director/Board Member | 71 | 15-12-31 |
Stephen Sullivan
BRD | Director/Board Member | 77 | 04-08-31 |
1st Jan change | Capi. | |
---|---|---|
-15.06% | 5.53B | |
+0.60% | 1.26B |